Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives $40.58 Consensus PT from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $40.5833.

Several research firms have commented on GMAB. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. HC Wainwright raised their price objective on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Wells Fargo & Company began coverage on shares of Genmab A/S in a research report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective for the company. Guggenheim lowered their target price on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Finally, Morgan Stanley assumed coverage on Genmab A/S in a report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price on the stock.

Genmab A/S Price Performance

GMAB stock opened at $25.10 on Friday. The business’s 50-day moving average is $30.19 and its two-hundred day moving average is $30.53. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The firm has a market capitalization of $16.13 billion, a P/E ratio of 16.19, a P/E/G ratio of 1.03 and a beta of 0.94. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $35.43.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GMAB. Orbis Allan Gray Ltd boosted its position in shares of Genmab A/S by 30.2% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after purchasing an additional 3,340,456 shares during the period. Alliancebernstein L.P. increased its position in Genmab A/S by 2.7% during the third quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock worth $335,957,000 after buying an additional 291,538 shares during the period. Paradigm Biocapital Advisors LP lifted its stake in Genmab A/S by 84.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock valued at $216,827,000 after buying an additional 3,222,983 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after buying an additional 1,334,919 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Genmab A/S by 23.8% in the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock valued at $107,580,000 after acquiring an additional 671,307 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.